Streetbeat News

Products Services

SYRE

Spyre Therapeutics has started dosing healthy volunteers in its first clinical trial of SPY001 for Inflammatory Bowel Disease. Interim pharmacokinetic and safety data are expected by the end of 2024. SPY002 is set to begin first-in-human studies in the second half of 2024. All three next-generation antibodies are on track to be in the clinic within 12 months.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:33 am

ITCI

Intra-Cellular Therapies announced positive topline results from its second Phase 3 trial evaluating Lumateperone as an adjunctive therapy for patients with Major Depressive Disorder. The trial met both its primary and key secondary endpoints.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:32 am

AFRM

Affirm shares are trading higher following a report suggesting Apple is discontinuing Apple Pay Later.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:31 am

AVGO

LEN

LZB

NEE

QQQ

SPY

Wall Street is showing mixed signals with tech stocks poised for a strong start, while the Dow and S&P 500 futures are slightly down. The market's direction will depend on upcoming retail sales data and Federal Reserve speeches. Analysts remain optimistic about the market's upward momentum, driven by potential Fed rate cuts and an AI-related stock rally. Key stocks in focus include La-Z-Boy, Lennar Corp, Broadcom, and NextEra Energy.

Portfolio Pulse from Shanthi Rexaline

June 18, 2024 | 11:31 am

NVDA

UBER

VOLVY

Waabi, an autonomous trucking startup, has raised $200 million in a Series B funding round with significant investments from Nvidia, Uber, and Volvo. The funds will support Waabi's goal of launching fully driverless trucks by 2025.

Portfolio Pulse from Benzinga Neuro

June 18, 2024 | 11:24 am

PYPD

PolyPid provides an update on its SHIELD II trial, which aims to address the rising rates of surgical site infections (SSIs) post-COVID. With 250 out of 600 patients enrolled, an unblinded interim analysis will be conducted after 400 patients complete their 30-day follow-up. Top-line results are expected in Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:18 am

PM

Philip Morris International shares are trading lower after its subsidiary, Swedish Match North America, received a subpoena from the Attorney General of the District of Columbia and announced the suspension of online sales on ZYN.com.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:18 am

STLA

Stellantis NV (NYSE:STLA) is recalling over 1 million vehicles in the U.S. due to an issue with the rearview camera image display. The recall affects various models including Dodge Durango, Chrysler Pacifica, and Jeep Grand Cherokee L. Dealers will update the radio software free of charge.

Portfolio Pulse from Anan Ashraf

June 18, 2024 | 11:17 am

ZNTL

Zentalis Pharmaceuticals announced that the FDA has placed a partial clinical hold on ZN-c3-001, DENALI, and TETON monotherapy studies of Azenosertib following two recent deaths due to presumed sepsis in the DENALI study.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:16 am

IMCR

Immunocore has announced the randomization of the first patient in the PRISM-MEL-301 trial of Brenetafusp (IMC-F106C; PRAME-A02) in combination with Nivolumab for first-line advanced or metastatic cutaneous melanoma.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:13 am